p53-R280S mutation confers lenvatinib resistance in hepatocellular carcinoma via Bcl-2-mediated anti-apoptotic signaling
Niangmei Cheng, Kexin Liu, Xin Qi, Leijie Cai, Yang Zhou, Fei Wang, Bixing Zhao, Yingchao Wang · 2026
Read p53-R280S mutation confers lenvatinib resistance in hepatocellular carcinoma via Bcl-2-mediated anti-apoptotic signaling by Niangmei Cheng, Kexin Liu, Xin Qi, Leijie Cai, Yang Zhou, Fei Wang, Bixing Zhao, Yingchao Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13638713.txt.
Description
Niangmei Cheng and seven colleagues published a 2026 laboratory study on why liver cancer can stop responding to the drug lenvatinib. That drug is a first-line treatment for liver cancer that cannot be removed by surgery, but resistance often develops over time.
Sequencing of resistant cancer cells pointed to a change in the p53 gene called R280S. Cells carrying that change survived lenvatinib better in dishes and in mouse tumors, partly because the altered protein raised Bcl-2, a protein that blocks cell death, and lowered BAX. The work names one route to resistance that future drugs might try to close.
Catalog record
| CREATOR | Niangmei Cheng, Kexin Liu, Xin Qi, Leijie Cai, Yang Zhou, Fei Wang, Bixing Zhao, Yingchao Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35268 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |